Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R.

Dement Geriatr Cogn Disord. 2011;32(3):164-70. doi: 10.1159/000332017. Epub 2011 Oct 13.

2.

SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease.

Guo LH, Westerteicher C, Wang XH, Kratzer M, Tsolakidou A, Jiang M, Grimmer T, Laws SM, Alexopoulos P, Bujo H, Kurz A, Perneczky R.

Eur Arch Psychiatry Clin Neurosci. 2012 Sep;262(6):529-34.

PMID:
22286501
3.

Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease.

Louwersheimer E, Ramirez A, Cruchaga C, Becker T, Kornhuber J, Peters O, Heilmann S, Wiltfang J, Jessen F, Visser PJ, Scheltens P, Pijnenburg YA, Teunissen CE, Barkhof F, van Swieten JC, Holstege H, Van der Flier WM; Alzheimer's Disease Neuroimaging Initiative and Dementia Competence Network..

Neurobiol Aging. 2015 Mar;36(3):1605.e13-20. doi: 10.1016/j.neurobiolaging.2014.12.007. Epub 2014 Dec 11.

PMID:
25659857
4.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
5.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

6.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative..

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

7.

Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease.

Kölsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J, Frölich L, Heuser I, Peters O, Schulz JB, Schwab SG, Maier W.

Neurosci Lett. 2008 Jul 25;440(1):68-71. doi: 10.1016/j.neulet.2008.05.049. Epub 2008 May 18.

PMID:
18541377
8.

Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.

Alexopoulos P, Guo LH, Tsolakidou A, Kratzer M, Grimmer T, Westerteicher C, Jiang M, Bujo H, Diehl-Schmid J, Kurz A, Perneczky R.

J Alzheimers Dis. 2012;28(3):543-52. doi: 10.3233/JAD-2011-110983.

PMID:
22045485
9.

Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM; Alzheimer's Disease Neuroimaging Initiative., Goate AM.

J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.

10.

Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.

Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.

J Alzheimers Dis. 2013;36(2):401-8. doi: 10.3233/JAD-122329.

PMID:
23609762
11.

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.

Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2011 Jan 4;76(1):69-79. doi: 10.1212/WNL.0b013e318204a397. Epub 2010 Dec 1.

12.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
13.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
14.

Implication of sex and SORL1 variants in italian patients with Alzheimer disease.

Cellini E, Tedde A, Bagnoli S, Pradella S, Piacentini S, Sorbi S, Nacmias B.

Arch Neurol. 2009 Oct;66(10):1260-6. doi: 10.1001/archneurol.2009.101.

PMID:
19822782
15.

Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.

Kettunen P, Larsson S, Holmgren S, Olsson S, Minthon L, Zetterberg H, Blennow K, Nilsson S, Sjölander A.

J Alzheimers Dis. 2015;44(4):1313-22. doi: 10.3233/JAD-142025.

PMID:
25420549
16.

A study of the SORL1 gene in Alzheimer's disease and cognitive function.

Liu F, Ikram MA, Janssens AC, Schuur M, de Koning I, Isaacs A, Struchalin M, Uitterlinden AG, den Dunnen JT, Sleegers K, Bettens K, Van Broeckhoven C, van Swieten J, Hofman A, Oostra BA, Aulchenko YS, Breteler MM, van Duijn CM.

J Alzheimers Dis. 2009;18(1):51-64. doi: 10.3233/JAD-2009-1137.

PMID:
19584446
17.

The SORL1 polymorphism rs985421 may confer the risk for amnestic mild cognitive impairment and Alzheimer's disease in the Han Chinese population.

Jin C, Zhang L, Xian Y, Liu X, Wu Y, Zhang F, Zhu J, Zhang G, Chen C, Gong R, Zhang L, Yuan J, Zhang F, Tian L, Wang G, Cheng Z.

Neurosci Lett. 2014 Mar 20;563:80-4. doi: 10.1016/j.neulet.2014.01.029. Epub 2014 Jan 29.

PMID:
24486888
18.

Association of SORL1 gene variants with Alzheimer's disease.

Kölsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, Kornhuber J, Frölich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den Bussche H, Hüll M, Kurz A, Rüther E, Henn FA, Maier W.

Brain Res. 2009 Apr 6;1264:1-6. doi: 10.1016/j.brainres.2009.01.044. Epub 2009 Feb 3.

PMID:
19368828
19.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

20.

An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.

Sun Y, Bresell A, Rantalainen M, Höglund K, Lebouvier T, Salter H; Alzheimer Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(4):1061-76. doi: 10.3233/JAD-142118.

PMID:
25720397

Supplemental Content

Support Center